Medical information Clinical review pending

Genetic Testing

SDHB Gene Pheochromocytoma Type 2 Genetic Test

Genetic test to identify mutations in the SDHB gene associated with an increased risk of pheochromocytoma and related tumors. Important for individuals with a family history of these conditions.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question

Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample: Blood sample (EDTA tube), Extracted DNA, or one drop of blood on an FTA card.
Results: 3 to 4 Weeks. Confirm with the laboratory before booking.
Preparation: Clinical history of the patient is required. A genetic counseling session to draw a pedigree chart of affected family members is recommended prior to testing. Confirm with the laboratory before booking.

Test priceKSh 40,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the SDHB Gene Pheochromocytoma Type 2 Genetic Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

Insurer or scheme name & policy / member number
A clinician's request / prescription for the test
Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

Full name *

Mobile number *

+254

Insurer or scheme

Policy / member number (optional)

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

WhatsApp the claims team Call us

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

✓Personal or family history of pheochromocytoma.
✓Personal or family history of paraganglioma.
✓Presence of symptoms suggestive of pheochromocytoma (e.g., persistent hypertension, palpitations).
✓Known family mutation in the SDHB gene.
✓Individuals seeking to understand their hereditary cancer risk.
✓Confirmation of diagnosis in suspected cases.

In plain language

What this test helps you understand

Identifies mutations in the SDHB gene, which are associated with an increased risk of developing pheochromocytoma and related tumors. This information can guide clinical management, surveillance strategies, and family counseling.

The SDHB Gene Pheochromocytoma Type 2 NGS Genetic DNA Test is a diagnostic tool used to identify specific genetic mutations linked to pheochromocytoma, a rare tumor. Understanding your genetic predisposition is key for early detection and management of potential cancer risks. This test uses Next Generation Sequencing (NGS) technology to analyze the SDHB gene, which is known to play a role in the development of pheochromocytomas and related tumors. Detecting mutations in this gene can help assess an individual's risk. This test is particularly relevant for individuals with a family history of pheochromocytoma, paraganglioma, or related cancers. Symptoms like persistent high blood pressure, palpitations, or unexplained weight loss might also warrant consideration for this test. A positive result indicates an increased risk, while a negative result can offer reassurance. Discussing your results with a healthcare provider is essential for understanding the implications and planning appropriate follow-up care.

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

Speak with us

We check the test and answer your questions before collection.

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

Understand your report

A counselor helps you understand the result and the next steps.

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →

PreparationClinical history of the patient is required. A genetic counseling session to draw a pedigree chart of affected family members is recommended prior to testing. Confirm with the laboratory before booking.

SampleBlood sample (EDTA tube), Extracted DNA, or one drop of blood on an FTA card.

MethodologyNext Generation Sequencing (NGS) Technology.

PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.

This test specifically analyzes the SDHB gene. It does not detect mutations in other genes associated with pheochromocytoma or other conditions. A negative result does not completely rule out a genetic predisposition. Confirm with the laboratory before booking.

Read your report

What common result terms mean

TermPlain-language meaning

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.

NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.

VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.

Questions people ask

Frequently asked questions

Pheochromocytoma is a rare tumor that usually develops in the adrenal glands, which are located on top of the kidneys. These tumors can cause the release of excess hormones, leading to symptoms like high blood pressure, headaches, and palpitations.

Individuals with a personal or family history of pheochromocytoma, paraganglioma, or related cancers should consider this test. Those experiencing symptoms suggestive of the condition may also benefit.

A positive result indicates that a mutation in the SDHB gene was detected. This may suggest an increased risk of developing pheochromocytoma or related conditions. Discuss the implications with your doctor.

Yes, genetic counseling before and after testing is highly recommended. It helps in understanding the test, interpreting the results, and discussing the implications for you and your family.

A sample can be collected as a blood draw, using extracted DNA, or via a single drop of blood on an FTA card. Confirm the required sample type with the laboratory.

The typical turnaround time is 3 to 4 weeks. Please confirm the current turnaround time with the laboratory before booking.

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

ACMG/AMP technical standards for sequence variant interpretation
ClinGen curation and gene–disease validity frameworks where applicable
LOINC-coded reporting for interoperable results
ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

Last updated: September 27, 2026
Medical review: not yet completed
Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →

Chat on WhatsApp